Literature DB >> 7904987

Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.

T Watanabe1, T Fukutomi, H Tsuda, I Adachi, T Nanasawa, H Yamamoto, K Abe.   

Abstract

The c-erbB-2 protein in breast cancer tissue extract was determined by using an enzyme-immunoassay (EIA) to see whether the quantitative determination of the oncoprotein correlates with the results of immunohistochemistry and other prognostic factors. Primary breast cancer from 104 patients was assayed for c-erbB-2 protein with an EIA that used two monoclonal antibodies directed against the extracellular domain of the protein. Pelleted tissue homogenate prepared routinely for hormone receptor assay was used as the starting material. The mean quantity of c-erbB-2 protein was 695 unit/mg protein (range 23 to 5939), and this correlated well with the results of immunohistochemical staining (P < 0.00001). It was found that 17.3% (18/104) of all tumors contained amounts of c-erbB-2 protein exceeding 1000 units/mg protein. All tumors with negative or weakly positive staining contained the oncoprotein as less than 1000 units/mg protein. The content of c-erbB-2 protein was correlated with the histologic grade (P = 0.0022), mitotic index (P = 0.0002) and degree of nuclear atypia (P = 0.013). It was inversely correlated with progesterone receptor (P = 0.006) and less strongly with estrogen receptor status (P = 0.016). Values of hormone receptor concentration and c-erbB-2 protein content showed a hyperbolic relationship that suggested biological interactions between c-erbB-2 protein and steroid hormone receptors. We conclude that c-erbB-2 protein in tissue extracts of primary breast cancer can be determined reliably by EIA, and it seems feasible to explore further the advantages of introducing EIA as a routine laboratory examination for providing additional information about the biological aspects of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7904987      PMCID: PMC5919113          DOI: 10.1111/j.1349-7006.1993.tb02835.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  36 in total

1.  Proto-oncogene amplification and human breast tumor phenotype.

Authors:  J Adnane; P Gaudray; M P Simon; J Simony-Lafontaine; P Jeanteur; C Theillet
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

2.  The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.

Authors:  J R Zabrecky; T Lam; S J McKenzie; W Carney
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

3.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

4.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

5.  An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.

Authors:  B C Langton; M C Crenshaw; L A Chao; S G Stuart; R W Akita; J E Jackson
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

6.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

7.  Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.

Authors:  K S Russell; M C Hung
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

8.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

9.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

Authors:  C Wright; S Nicholson; B Angus; J R Sainsbury; J Farndon; J Cairns; A L Harris; C H Horne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

10.  Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; Y Tanaka; T Hirota; S Tsugane; M Shiraishi; K Toyoshima; T Yamamoto; M Terada
Journal:  Jpn J Cancer Res       Date:  1990-04
View more
  1 in total

1.  HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.

Authors:  Andrew R Green; Fabrício F T Barros; Tarek M A Abdel-Fatah; Paul Moseley; Christopher C Nolan; Alice C Durham; Emad A Rakha; Stephen Chan; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2014-04-06       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.